RISK: Health, Safety & Environment (1990-2002)


Mr. Cunningham stresses the broad scope of biotechnological innovations. Besides endorsing the need for a new oversight commission to deal with potential social issues, he suggests, for example, that some products should be treated like biologics rather than new drugs.

Repository Citation

Brian C. Cunningham, Impact of the Human Genome Project at the Interface between Patent and FDA Laws, 7 RISK 253 (1996).